A 2026 review in Cryobiology examines the convergence of cryobiology and tissue engineering, including vitrification of scaffold-based and scaffold-free tissue-engineered constructs, organoids, controlled-rate freezing, cryobioprinting, and scale-up using polymers and technical devices. It also covers xeno-free and dimethyl sulfoxide-free cryoprotective systems, biologically inspired nanomaterials, and preclinical animal studies supporting clinical translation.[1]
The technical value for the Ark is a potential shift from preserving isolated cells to preserving functional three-dimensional tissues. Scaffold-integrated cryoprotective agents, nanoparticles, cold-responsive polymers, and ice-recrystallization or devitrification inhibitors may improve post-thaw viability and function, while cryobioprinting could support fabrication, storage, and on-demand deployment. The principal risks remain nonuniform heat and mass transfer, cryoprotectant toxicity, ice damage, structural failure, and uncertain long-duration stability in lunar radiation and power-loss conditions.[1][3][4]
The Ark team should establish a preservation research track covering vitrification, controlled-rate cooling, DMSO-free and xeno-free formulations, organoids, bioprinted tissues, nanowarming, and cryobioprinting. Qualification must measure post-thaw viability, proliferation, differentiation, mechanical integrity, sterility, radiation tolerance, and function after simulated lunar storage, with redundant thermal control, passive backup, and periodic witness samples to detect degradation across century-scale archives.[1][2][4]